The Effect of Oxytocin on Reinforcement Learning

Sponsor

University of Electronic Science and Technology of China (Other)

Overall Status

Recruiting

CT.gov ID

NCT05245708

Collaborator

(none)

Enrollment

Location

Arms

Anticipated Duration (Months)

6.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main aim of the study is to investigate whether intranasal oxytocin has effects on reinforcement learning under dynamic environment based on behavioral and electroencephalogram (EEG) responses.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: Intranasal oxytocin Drug: intranasal placebo	N/A

Detailed Description

A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. A probabilistic reward learning task starts 45 minutes after treatment with behavioral (response time and accuracy) and EEG data (ERP components such as FRN, ERN and P300) being collected during this task. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), the Cognitive Flexibility Inventory(CFI), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the learning task.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

80 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Basic Science

Official Title:

Common and Distinct Effects of Oxytocin on Reinforcement Learning Under Stable and Volatile Associations

Actual Study Start Date :

Apr 15, 2021

Anticipated Primary Completion Date :

Mar 20, 2022

Anticipated Study Completion Date :

Apr 15, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: oxytocin a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.	Drug: Intranasal oxytocin Each subject will be assigned to intranasal administration of oxytocin (24 IU).
Experimental: placebo a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.	Drug: intranasal placebo Each subject will be assigned to intranasal placebo.

Arm

Intervention/Treatment

Experimental: oxytocin

a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.

Drug: Intranasal oxytocin

Each subject will be assigned to intranasal administration of oxytocin (24 IU).

Experimental: placebo

a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.

Drug: intranasal placebo

Each subject will be assigned to intranasal placebo.

Outcome Measures

Primary Outcome Measures

Behavioral index: chioce accuracy [45-75 minutes after treatment administration]
The accuracy of subjects choosing the better option.

Secondary Outcome Measures

ERP components: ERN, FRN, P300 [45-75 minutes after treatment administration]
ERN and FRN are indices of reward expectancy and prediction error in reinforcement learning. P300 is associated with attention allocation.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 28 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Healthy subjects without any past or present psychiatric or neurological disorders.

Exclusion Criteria:

History of brain injury medical or mental illness.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Electronic Science and Technology of China (UESTC)	Chengdu	Sichuan	China	611731

Sponsors and Collaborators

University of Electronic Science and Technology of China

Investigators

Principal Investigator: Yao Shuxia, Dr, University of Electronic Science and Technology of China

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Shuxia Yao, Associate Professor, University of Electronic Science and Technology of China

ClinicalTrials.gov Identifier:

NCT05245708

Other Study ID Numbers:

UESTC-neuSCAN-83

First Posted:

Feb 18, 2022

Last Update Posted:

Feb 18, 2022

Last Verified:

Feb 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Shuxia Yao, Associate Professor, University of Electronic Science and Technology of China

oxytocin

learning

Additional relevant MeSH terms:

Oxytocin

Study Results

No Results Posted as of Feb 18, 2022